ArticleEuropean journal of immunology2021
Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans.
Article in European journal of immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Pooled it
- A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.International journal of biological sciences · 2022Pooled it
- Contrasting effects of SARS-CoV-2 vaccination vs. infection on antibody and TCR repertoires.PloS one · 2026Article
- The impact of Omicron infection on antibody response and attenuation: a six-month follow-up study.BMC infectious diseases · 2025Article
- Seroprevalence of anti-SARS-CoV-2 IgG antibodies among vaccinated healthcare workers in Bamako, Mali.African health sciences · 2025Article
- Contrasting Effects of SARS-CoV-2 Vaccination vs. Infection on Antibody and TCR Repertoires.bioRxiv : the preprint server for biology · 2025Article
- Machine learning approaches to dissect hybrid and vaccine-induced immunity.Communications medicine · 2025Article
- COVID-19 Seroprevalence in Romania: Insights from a Nationwide Antibody Study.Epidemiologia (Basel, Switzerland) · 2025Article
- Incidence of SARS-CoV-2 reinfection among blood donors from two Brazilian states in the post-vaccination period: a prospective cohort study.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Humoral and Innate Immunological Profile of Paediatric Recipients of Pfizer-BioNTech BNT162b2 mRNA Vaccine.Microorganisms · 2024Article
- Article
- Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study.Journal of clinical medicine · 2024Article
- Article
- Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.Frontiers in cellular and infection microbiology · 2024Article
- Serological survey in a university community after the fourth wave of COVID-19 in Senegal.PloS one · 2024Article
- Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022.Emerging microbes & infections · 2023Article
- Weaker SARS-CoV-2 vaccine responses in nonalcoholic fatty liver disease with advanced liver fibrosis.Vaccine: X · 2023Article
- Immune responses of lung transplant recipients against SARS-CoV-2 and common respiratory coronaviruses: Evidence for pre-existing cross-reactive immunity.Transplant immunology · 2023Article
- Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021.Journal of virological methods · 2023Article
- SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants.Emerging microbes & infections · 2023Observational
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
Abstract
Most subjects develop antibodies to SARS-CoV-2 following infection. In order to estimate the duration of immunity induced by SARS-CoV-2 it is important to understand for how long antibodies persist after infection in humans. Here, we assessed the persistence of serum antibodies following WT SARS-CoV-2 infection at 8 and 13 months after diagnosis in 367 individuals. The SARS-CoV-2 spike IgG (S-IgG) and nucleoprotein IgG (N-IgG) concentrations and the proportion of subjects with neutralizing antibodies (NAb) were assessed. Moreover, the NAb titers among a smaller subset of participants (n = 78) against a WT virus (B) and variants of concern (VOCs): Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) were determined. We found that NAb against the WT virus persisted in 89% and S-IgG in 97% of subjects for at least 13 months after infection. Only 36% had N-IgG by 13 months. The mean S-IgG concentrations declined from 8 to 13 months by less than one third; N-IgG concentrations declined by two-thirds. Subjects with severe infection had markedly higher IgG and NAb levels and are expected to remain seropositive for longer. Significantly lower NAb titers against the variants compared to the WT virus, especially after a mild disease, suggests reduced protection against VOCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.